

COPY OF PAPERS
ORIGINALLY FILED

DT17 Rec'd PCT/PTO 31 JUL 2002

Receipt
pa



Attorney's Docket No. 5470.276

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: MacDonald et al.

Application No.: 10/069,305

Filing Date: To be assigned

For: **ANTIBODY DEPENDENT ENHANCEMENT (ADE) OF ALPHAVIRUS
INFECTION**

Date: July 26, 2002

Commissioner for Patents
Washington, DC 20231

RECEIVED
SEP 13 2002

REQUEST FOR CORRECTED FILING RECEIPT TECHNOLOGY CENTER R3700

Sir:

In reviewing the filing receipt (copy attached) for the above-referenced application, Applicant notes that the name of the second named inventor appears as "Robert E. Johnson".

Applicant respectfully requests that the spelling of this inventor's name be corrected to read --Robert E. Johnston--. Applicant also respectfully requests that a corrected filing receipt be issued.

Respectfully submitted,

Karen A. Magri
Registration No. 41,965

Customer No.



20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, Washington, DC 20231, on July 26, 2002.

Sloan Hobbs

COPY OF PAPERS
ORIGINALLY FILED

07-22-02A10:01 RCVD

KAM




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/069,305	06/06/2002	3761	1974	5470.276	10	45	9

20792
MYERS BIGEL SIBLEY & SAJOVEC
PO BOX 37428
RALEIGH, NC 27627



CONFIRMATION NO. 1963

FILING RECEIPT



OC000000008452780

Date Mailed: 07/16/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Gene H MacDonald, Chapel Hill, NC;
Robert E Johnson, Chapel Hill, NC;

RECEIVED

SEP 13 2002

TECHNOLOGY CENTER R3700

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US00/23845 08/30/2000
WHICH CLAIMS BENEFIT OF 60/151,718 08/31/1999
AND CLAIMS BENEFIT OF 60/177,435 01/21/2000

Foreign Applications

Projected Publication Date: Not Applicable, filed prior to November 29,2000

Non-Publication Request: No

Early Publication Request: No

Title

Antibody dependent enhancement (ade) of alphavirus infection

Preliminary Class

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).